Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1115 | 981 | 1314 | 870 | 1689 | - |
Fund Return | 11.49% | -1.91% | 31.39% | -4.55% | 11.06% | - |
Place in category | 36 | 233 | 3 | 343 | 13 | - |
% in Category | 7 | 59 | 1 | 89 | 3 | - |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
DNCA Invest Eurose Class AD shares | 2.52B | 2.96 | 2.70 | 2.34 | ||
DNCA Invest Eurose Class A shares | 2.52B | 2.96 | 2.71 | 2.34 | ||
DNCA Invest Eurose Class I shares E | 2.52B | 3.58 | 3.44 | 3.07 | ||
DNCA Invest Europe Growth Class A s | 913.94M | 0.14 | -5.43 | 7.96 | ||
DNCA Invest Europe Growth Class B s | 913.94M | -0.19 | -5.80 | 7.56 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
DNCA Invest Europe Growth Class A s | 913.94M | 0.14 | -5.43 | 7.96 | ||
DNCA Invest Europe Growth Class B s | 913.94M | -0.19 | -5.80 | 7.56 | ||
DNCA Invest Europe Growth Class F s | 913.94M | 1.18 | -4.28 | 9.11 | ||
DNCA Invest Europe Growth Class I s | 913.94M | 1.01 | -4.47 | 8.97 | ||
LU1330191385 | 836.23M | -0.46 | 7.72 | - |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Novo Nordisk B | DK0062498333 | 8.67 | 748.9 | -3.23% | |
Tryg | DK0060636678 | 5.71 | 156.5 | -1.88% | |
Flutter Entertainment | IE00BWT6H894 | 5.08 | 19,270.0 | +0.23% | |
ASML Holding | NL0010273215 | 4.87 | 630.30 | +0.48% | |
AstraZeneca | GB0009895292 | 4.67 | 9,990.0 | +0.05% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Buy | Neutral | Buy |
Technical Indicators | Neutral | Sell | Strong Buy |
Summary | Neutral | Neutral | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review